SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001169245-22-000033
Filing Date
2022-04-04
Accepted
2022-04-04 16:35:30
Documents
14
Period of Report
2022-04-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K phas-20220404.htm   iXBRL 8-K 38440
2 EX-99.1 ex991bentracimabphase2bfin.htm EX-99.1 20587
6 image.jpg GRAPHIC 10237
  Complete submission text file 0001169245-22-000033.txt   225480

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20220404.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20220404_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20220404_pre.xml EX-101.PRE 13731
8 EXTRACTED XBRL INSTANCE DOCUMENT phas-20220404_htm.xml XML 11441
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

IRS No.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 22802859
SIC: 2834 Pharmaceutical Preparations